600538.SH
Beihai Gofar Chuanshan Biological Co., Ltd.
SSE · Healthcare · Medical - Pharmaceuticals · CN
CNY 5.13
−1.54%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 332.3M | 328.2M | 340.5M | 369.2M | 459.7M |
| Cost of Revenue | 255.1M | 254.5M | 253.2M | 277.5M | 331.5M |
| Gross Profit | 77.1M | 73.7M | 87.3M | 91.7M | 128.2M |
| Operating Expenses | |||||
| R&D Expense | 7.7M | 7.4M | 8.2M | 12.8M | 8.4M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 57.6M | 56.6M | 53.0M | 54.0M | 51.3M |
| Selling & Marketing Expense | 30.7M | 30.4M | 33.9M | 36.7M | 34.9M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 100.9M | 98.8M | 98.1M | 103.9M | 94.3M |
| Cost and Expenses | 356.0M | 353.3M | 351.3M | 381.3M | 425.8M |
| Operating Income (EBIT) | (95.6M) | (84.4M) | (91.7M) | (77.8M) | 42.3M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (95.4M) | (84.8M) | (92.0M) | (77.6M) | 42.1M |
| Income Tax Expense | 1.9M | 1.9M | (70.0K) | 3.6M | 5.5M |
| Bottom Line | |||||
| Net Income | (98.3M) | (87.6M) | (93.9M) | (82.3M) | 34.8M |
| Earnings from Cont. Ops | (97.3M) | (86.6M) | (91.9M) | (81.2M) | 36.6M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (98.3M) | (87.6M) | (93.9M) | (82.3M) | 34.8M |
| Per Share | |||||
| Basic EPS | (CN¥0.18) | (CN¥0.17) | (CN¥0.18) | (CN¥0.16) | CN¥0.07 |
| Diluted EPS | (CN¥0.18) | (CN¥0.17) | (CN¥0.18) | (CN¥0.16) | CN¥0.07 |
| Revenue Per Share | CN¥0.44 | CN¥0.64 | CN¥0.65 | CN¥0.72 | CN¥0.92 |
| Shares | |||||
| Basic Shares Outstanding | 755.0M | 515.4M | 521.4M | 514.4M | 497.7M |
| Diluted Shares Outstanding | 755.0M | 515.4M | 521.4M | 514.4M | 497.7M |
| Profitability Metrics | |||||
| EBITDA | — | (69.1M) | (76.1M) | (62.0M) | 56.9M |
| D&A | — | 15.3M | 15.6M | 15.7M | 14.6M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026